

University of Groningen

Antibody imaging as biomarker in early cancer drug development and treatment

Lamberts, Laetitia Elisabeth

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version

Publisher's PDF, also known as Version of record

Publication date:

2016

[Link to publication in University of Groningen/UMCG research database](#)

Citation for published version (APA):

Lamberts, L. E. (2016). *Antibody imaging as biomarker in early cancer drug development and treatment*. [Thesis fully internal (DIV), University of Groningen]. Rijksuniversiteit Groningen.

Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license. More information can be found on the University of Groningen website: <https://www.rug.nl/library/open-access/self-archiving-pure/taverne-amendment>.

Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): <http://www.rug.nl/research/portal>. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.

ANTIBODY IMAGING AS BIOMARKER IN
EARLY CANCER DRUG DEVELOPMENT
AND TREATMENT

Laetitia Elisabeth Lamberts

The research presented in this thesis was conducted at the Department of Medical Oncology of the University of Groningen. This research project was financially supported by Rijksuniversiteit Groningen, Universitair Medisch Centrum Groningen, Center for Translational Molecular Medicine (CTMM) project Mammary carcinoma Molecular Imaging for Diagnosis and Therapeutics (MAMMOTH), Genentech Inc.

The printing of this thesis was financially supported by the Stichting Werkgroep Interne Oncologie, Rijksuniversiteit Groningen, Universitair Medisch Centrum Groningen, and Mr and Mrs Lamberts- de Vries, and is gratefully acknowledged.

Lamberts, Laetitia Elisabeth

Antibody imaging as biomarker in early cancer drug development and treatment
Thesis, University of Groningen, The Netherlands

© 2016 L.E. Lamberts

All rights are reserved. No part of this thesis may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, without prior permission of the author.

Cover: Dolinda Toepoel, www.dolindatoepoel.com

Lay-out: Douwe Oppewal, www.oppewal.nl

Printed by: Ipskamp Drukkers, Enschede



rijksuniversiteit
 groningen

Antibody imaging as biomarker in early cancer drug development and treatment

Proefschrift

ter verkrijging van de graad van doctor aan de
Rijksuniversiteit Groningen
op gezag van de
rector magnificus prof. dr. E. Sterken
en volgens besluit van het College voor Promoties.

De openbare verdediging zal plaatsvinden op

maandag 23 mei om 14.30 uur

door

Laetitia Elisabeth Lamberts

geboren op 23 januari 1986
te Groningen

Promotores

Prof. dr. E.G.E. de Vries

Prof. dr. J.A. Gietema

Copromotores

Dr. C.P. Schröder

Dr. A.H. Brouwers

Beoordelingscommissie

Prof. dr. H.J. Guchelaar

Prof. dr. G.A. Langendijk

Prof. dr. S. Sleijfer

Paranimfen

C.N.H. Abheiden

F. Bensch

Contents

Chapter 1	General introduction	9
Chapter 2	Molecular imaging of tumors with radioactive labeled antibodies from laboratory to the clinic. <i>AACR education book 2012: 227-32</i>	17
Chapter 3	Antibody imaging in anticancer drug development. <i>J Clin Oncol 2015; 33:1491-504</i>	25
Chapter 4	Functional Genomic mRNA Profiling of a large cancer data base demonstrates mesothelin overexpression in a broad range of tumor types. <i>Oncotarget 2015; 6: 28164-72</i>	49
Chapter 5	Imaging the distribution of an antibody-drug conjugate constituent targeting mesothelin with ⁸⁹ Zr and IRDye 800CW in mice bearing human pancreatic tumor xenografts. <i>Oncotarget 2015; 6: 42081-90</i>	63
Chapter 6	ImmunoPET with naked mesothelin antibody in pancreatic and ovarian cancer patients before anti-mesothelin antibody-drug conjugate treatment. <i>Clinical Cancer Research 2015; Nov 20 (Epub)</i>	81
Chapter 7	Phase I study of DMOT4039A, an antibody-drug conjugate targeting mesothelin, in patients with unresectable pancreatic or platinum-resistant ovarian cancer. <i>Molecular Cancer Therapeutics 2016; Jan 28 (Epub)</i>	101
Chapter 8	Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): the ZEPHIR Trial. <i>Annals of Oncology 2015; Nov 23 (Epub)</i>	119
Chapter 9	Tumor specific uptake of fluorescent bevacizumab-IRDye800CW: a safe tool in image-guided surgery in patients with primary breast cancer. <i>Submitted</i>	135
Chapter 10	Summary and future perspectives	161
Chapter 11	Nederlandse samenvatting (Summary in Dutch)	171
	Dankwoord (Acknowledgements)	179
	Publications	185

